Literature DB >> 19242286

Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes.

James R Rodrigue1, William Balistreri, Barbara Haber, Maureen M Jonas, Parvathi Mohan, Jean P Molleston, Karen F Murray, Michael R Narkewicz, Philip Rosenthal, Lesley J Smith, Kathleen B Schwarz, Patricia Robuck, Bruce Barton, Regino P González-Peralta.   

Abstract

OBJECTIVE: Hepatitis C virus (HCV) infection is associated with decreased quality of life (QOL) and neurocognitive dysfunction in adults, but little is known about its impact on children and their caregivers. PATIENTS AND METHODS: We studied the QOL, behavioral, emotional, and cognitive functioning of 114 treatment-naïve children with HCV enrolled in a placebo-controlled, randomized, multisite clinical trial evaluating peginterferon alpha-2a alone or with ribavirin. Baseline assessment included measures of children's QOL, cognitive functioning, behavioral adaptation, and depression. Caregivers' QOL also was assessed.
RESULTS: Relative to published normative data, caregivers were more likely to believe that their children's health was poor and would likely worsen (t = 3.93; P < 0.0001), and reported higher concern about their children's health status (t = 6.63; P < 0.0001) and that this concern limited family activities (t = 2.45; P < 0.01); they also viewed their children as having more internalizing behavioral problems (t = 1.98; P < 0.05). Only 2 (2%) children had a score in the clinically depressed range. Children with HCV had worse cognitive functioning than the normative sample but significantly better functioning than children with attention-deficit/hyperactivity disorder. Caregivers' QOL scores did not differ significantly from the normative sample, but infected mothers had lower QOL than noninfected caregivers. Caregivers were highly distressed about their children's medical circumstances.
CONCLUSIONS: Although HCV infection, in its early stages, does not lead to global impairment in QOL, cognitive, behavioral, or emotional functioning in children, it is associated with higher caregiver stress and strain on the family system, and it may be associated with some cognitive changes in children.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242286      PMCID: PMC2649743          DOI: 10.1097/MPG.0b013e318185998f

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  27 in total

1.  The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.

Authors:  J G McHutchison; J E Ware; M S Bayliss; S Pianko; J K Albrecht; S Cort; I Yang; M P Neary
Journal:  J Hepatol       Date:  2001-01       Impact factor: 25.083

2.  Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.

Authors:  Daniel M Forton; Howard C Thomas; Christine A Murphy; Joanna M Allsop; Graham R Foster; Janice Main; Keith A Wesnes; Simon D Taylor-Robinson
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

3.  Liver histology and alanine aminotransferase levels in children and adults with chronic hepatitis C infection.

Authors:  Karen F Murray; Laura S Finn; Shari L Taylor; Kristy D Seidel; Anne M Larson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-11       Impact factor: 2.839

4.  The impact of diagnosis of hepatitis C virus on quality of life.

Authors:  A J Rodger; D Jolley; S C Thompson; A Lanigan; N Crofts
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

5.  The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life.

Authors:  Joseph K Lim; Ruth Cronkite; Mary K Goldstein; Ramsey C Cheung
Journal:  J Clin Gastroenterol       Date:  2006-07       Impact factor: 3.062

6.  Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition.

Authors:  C Goulding; P O'Connell; F E Murray
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

7.  Predictors of psychological adjustment in school-age children infected with HIV.

Authors:  P J Bachanas; K A Kullgren; K S Schwartz; B Lanier; J S McDaniel; J Smith; S Nesheim
Journal:  J Pediatr Psychol       Date:  2001-09

8.  The Child Health Questionnaire in children with diabetes: cross-sectional survey of parent and adolescent-reported functional health status.

Authors:  M Wake; K Hesketh; F Cameron
Journal:  Diabet Med       Date:  2000-10       Impact factor: 4.359

9.  Clinical spectrum and histopathologic features of chronic hepatitis C infection in children.

Authors:  Parvathi Mohan; Camilla Colvin; Chevelle Glymph; Roma R Chandra; David E Kleiner; Kantilal M Patel; Naomi L C Luban; Harvey J Alter
Journal:  J Pediatr       Date:  2007-02       Impact factor: 4.406

Review 10.  Central nervous system changes in hepatitis C virus infection.

Authors:  Daniel M Forton; Simon D Taylor-Robinson; Howard C Thomas
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-04       Impact factor: 2.566

View more
  29 in total

1.  The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

Authors:  Kathleen B Schwarz; Regino P Gonzalez-Peralta; Karen F Murray; Jean P Molleston; Barbara A Haber; Maureen M Jonas; Philip Rosenthal; Parvathi Mohan; William F Balistreri; Michael R Narkewicz; Lesley Smith; Steven J Lobritto; Stephen Rossi; Alexandra Valsamakis; Zachary Goodman; Patricia R Robuck; Bruce A Barton
Journal:  Gastroenterology       Date:  2010-10-28       Impact factor: 22.682

Review 2.  Hepatitis B and C.

Authors:  Wikrom Karnsakul; Kathleen B Schwarz
Journal:  Pediatr Clin North Am       Date:  2017-06       Impact factor: 3.278

3.  Neuropsychological functioning and health-related quality of life: pediatric acute liver failure study group results.

Authors:  Lisa G Sorensen; Katie Neighbors; Song Zhang; Christine A Limbers; James W Varni; Vicky L Ng; Robert H Squires; Estella M Alonso
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-01       Impact factor: 2.839

4.  Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.

Authors:  Alexander J Millman; Noele P Nelson; Claudia Vellozzi
Journal:  Curr Epidemiol Rep       Date:  2017-04-20

5.  Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children.

Authors:  James R Rodrigue; William Balistreri; Barbara Haber; Maureen M Jonas; Parvathi Mohan; Jean P Molleston; Karen F Murray; Michael R Narkewicz; Philip Rosenthal; Lesley J Smith; Steven J Lobritto; Kathleen B Schwarz; Patricia R Robuck; Bruce Barton; Regino P González-Peralta
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

Review 6.  Vertical hepatitis C virus transmission: Main questions and answers.

Authors:  Grazia Tosone; Alberto Enrico Maraolo; Silvia Mascolo; Giulia Palmiero; Orsola Tambaro; Raffaele Orlando
Journal:  World J Hepatol       Date:  2014-08-27

7.  Health-related Quality of Life in Pediatric Patients With Chronic Hepatitis B Living in the United States and Canada.

Authors:  Sarah Jane Schwarzenberg; Simon C Ling; Yona Keich Cloonan; Hsing-Hua S Lin; Donna M Evon; Karen F Murray; Norberto Rodriguez-Baez; Philip Rosenthal; Jeffrey Teckman; Kathleen B Schwarz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-05       Impact factor: 2.839

8.  Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease.

Authors:  K D Kistler; J Molleston; A Unalp; S H Abrams; C Behling; J B Schwimmer
Journal:  Aliment Pharmacol Ther       Date:  2009-10-23       Impact factor: 8.171

Review 9.  Hepatitis C genotype 4: The past, present, and future.

Authors:  Tawhida Y Abdel-Ghaffar; Mostafa M Sira; Suzan El Naghi
Journal:  World J Hepatol       Date:  2015-12-08

10.  Managing pediatric hepatitis C: current and emerging treatment options.

Authors:  Wikrom Karnsakul; Mary Kay Alford; Kathleen B Schwarz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.